Meeting
2013 Breast Cancer Symposium
Hormone-receptor–positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy.
Authors
Nicole M. Engel-Nitz
OptumInsight, Eden Prairie, MN
Nicole M. Engel-Nitz , Yanni Hao , Jaqueline Willemann Rogerio , James D. Turnbull , Gabriel Gomez Rey , Jane Sullivan , Arthur H. Rossof
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B
Track
Survivorship and Health Policy,Systemic Therapy
Sub Track
Advanced Disease
Citation
J Clin Oncol 31, 2013 (suppl 26; abstr 164)
DOI
10.1200/jco.2013.31.26_suppl.164
Abstract #
164
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.
First Author: Sunil Verma
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
First Author: Dejan Juric
Poster
2021 ASCO Annual Meeting
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
First Author: Erika P. Hamilton